Guidance to bone morbidity in children and adolescents undergoing allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is the standard of care in children with very high-risk acute leukemia.1-3 Through advances in donor selection and supportive care strategies, cure rates in patients with high-risk acute lymphoblastic leukemia (ALL) are approaching 70% in large multi-institutional trials.4 However, this success comes at the cost of complications and sequelae from chemotherapy and HSCT with negative impact on quality of life (QoL).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Michaela Kuhlen, Marina Kunstreich, Riitta Niinimaki, Desiree Dunstheimer, Anita Lawitschka, Edit Bardit, Andr é Willasch, Peter Bader, Wolfgang Högler, Christina Peters, Adriana Balduzzi Tags: Review article Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biology | Chemotherapy | Children | Hematology | Legislation | Leukemia | Stem Cell Therapy | Stem Cells | Transplants